| Trial ID # | NCT02853318 |
| Phase | II |
| Drug Class | Immunotherapy: Checkpoint Inhibitors/PD-1 |
| Drug Name | Pembrolizumab |
| Alternate Drug Names | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 |
| Drugs in Trial | Bevacizumab, Cyclophosphamide, Pembrolizumab |
| Eligible Participant | Platinum resistant or refractory ovarian cancer |
| Patients Enrolled | 30, mean of 3.8 prior therapies |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | CBR, ORR, DCR, PFS, evaluated per irRECIST |
| Efficacy | pembrolizumab 200 mg in combination with bevacizumab 15 mg/kg every 3 weeks and oral cyclophosphamide 50 mg every day ORR: 43.3% (3CR, 10PR, n=30) |
| Clinically Significant Adverse Events | Serious AE: |
| Conclusion | Pembrolizumab+bevacizumab+cyclophosphamide is well tolerated and demonstrates clinical benefit and durable treatment responses |
| Reference | Zsiros E et al. Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncol (2020) 7(1):78-85 |